Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression
- PMID: 18584413
- DOI: 10.1080/09513590802095845
Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression
Abstract
Background: The majority of human breast cancers and in addition most breast-cancer cell lines express gonadotropin-releasing hormone (GnRH) receptors. Their proliferation and in addition their bone-directed invasion is time- and dose-dependently reduced by GnRH. Osteolytic metastases are characteristic for breast cancer-derived metastasis. Since the osteolytic activity depends on the receptor activator of nuclear factor-kappaB (NFkappaB) ligand (RANKL)/osteoprotegerin (OPG) ratio, we analyzed RANKL and OPG expression in different breast-cancer cell lines.
Methods: Different human breast-cancer cell lines were tested for expression of GnRH receptor, OPG and RANKL. Using a co-culture system of breast-cancer cell lines and human primary osteoblasts (hOB), we analyzed the expression of OPG and RANKL in the GnRH receptor-positive breast-cancer cell line HCC70 co-cultured with or without hOB. In addition, we assessed the effects of GnRH analog treatment on OPG and RANKL mRNA and protein levels.
Results: All tested breast-cancer cell lines were GnRH receptor-positive. The majority of these cell lines expressed OPG but not RANKL. The HCC70 breast-cancer cell line derived from an invasive ductal carcinoma with metastases was positive for both OPG and RANKL. The expression of RANKL by HCC70 cells was increased when co-cultured with hOB. Treatment with GnRH analogs reduced the expression of RANKL by HCC70 cells co-cultured with hOB. No effects were observed on breast cancer OPG expression.
Conclusions: These data show that the majority of human breast-cancer cell lines express OPG but not RANKL. The HCC70 breast-cancer cell line is RANKL-positive. Co-culture of HCC70 breast cancer cells with hOB increases RANKL expression. Activation of tumor GnRH receptors reduces RANKL expression. These experiments demonstrate that HCC70 breast cancer cells are able to activate osteoclasts directly via RANKL. The interaction between HCC70 breast cancer cells and osteoblasts induces osteoclastogenesis through an increase of RANKL expression. GnRH seems to play an important role by modulating the RANKL expression in HCC70 breast cancer cells.
Similar articles
-
Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.Prostate. 2007 Jun 1;67(8):840-8. doi: 10.1002/pros.20574. Prostate. 2007. PMID: 17394194
-
Osteoprotegrin and the bone homing and colonization potential of breast cancer cells.J Cell Biochem. 2008 Jan 1;103(1):30-41. doi: 10.1002/jcb.21382. J Cell Biochem. 2008. PMID: 17471510
-
RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.Prostate. 2008 Jan 1;68(1):92-104. doi: 10.1002/pros.20678. Prostate. 2008. PMID: 18008334
-
The RANK/RANKL/OPG triad in cancer-induced bone diseases.Cancer Metastasis Rev. 2006 Dec;25(4):541-9. doi: 10.1007/s10555-006-9021-3. Cancer Metastasis Rev. 2006. PMID: 17180711 Review.
-
[The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].Bull Cancer. 2011 Jul;98(7):837-46. doi: 10.1684/bdc.2011.1398. Bull Cancer. 2011. PMID: 21700551 Review. French.
Cited by
-
Association analyses suggest the effects of RANK and RANKL on age at menarche in Chinese women.Climacteric. 2012 Feb;15(1):75-81. doi: 10.3109/13697137.2011.587556. Epub 2011 Oct 24. Climacteric. 2012. PMID: 22023082 Free PMC article.
-
Butein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of receptor activator of nuclear factor-kappaB ligand signaling.Int J Cancer. 2011 Nov 1;129(9):2062-72. doi: 10.1002/ijc.25868. Epub 2011 Mar 11. Int J Cancer. 2011. PMID: 21170936 Free PMC article.
-
RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis.Geburtshilfe Frauenheilkd. 2012 May;72(5):385-391. doi: 10.1055/s-0031-1298276. Geburtshilfe Frauenheilkd. 2012. PMID: 25298541 Free PMC article.
-
Breast cancer at bone metastatic sites: recent discoveries and treatment targets.J Cell Commun Signal. 2011 Jun;5(2):85-99. doi: 10.1007/s12079-011-0117-3. Epub 2011 Jan 19. J Cell Commun Signal. 2011. PMID: 21484191 Free PMC article.
-
Gene polymorphisms in RANKL/RANK/OPG pathway are associated with ages at menarche and natural menopause in Chinese women.BMC Womens Health. 2015 Apr 13;15:32. doi: 10.1186/s12905-015-0192-3. BMC Womens Health. 2015. PMID: 25884698 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical